BioCentury | Jul 29, 2020
Finance

Enthera’s €28M series A latest sign of growth for Italy’s biotech ecosystem

U.S. and European investors are backing the largest-ever series A financing for an Italian biotech, autoimmune play Enthera s.r.l. Enthera raised €28 million ($32.8 million) in the round, which was led by existing investor Sofinnova...
BioCentury | Aug 29, 2019
Distillery Techniques

STAT3-based gene signature to predict response to glioblastoma targeted therapy

...elevated in cells with low STAT3 signaling, and an shRNA against the IGF1R ligand IGFBP2 (insulin-like growth factor binding protein 2...
...Singapore, Singapore email: carol_tang@nni.com.sg Claire Quang Agency for Science Technology and Research National University of Singapore Duke-NUS Medical School Insulin-like growth factor (IGF) binding protein 2 (IGFBP2) Insulin-like...
BioCentury | Jul 31, 2019
Financial News

Alizé seeks to build out company with largest European A round this year

...licensed from Massachusetts General Hospital to treat hypoparathyroidism, and AZP-3404 is a small peptide targeting IGFBP2...
...million) this year. Targets: PTH - parathyroid hormone; IGFBP2 - insulin-like growth factor binding protein 2 Stephen Hansen, Associate Editor Alize Pharma LSP Insulin-like growth factor (IGF) binding protein 2 (IGFBP2) Parathyroid...
BioCentury | Aug 9, 2018
Distillery Techniques

Drug platforms

...In human induced pluripotent stem (iPS) cell-derived megakaryocyte cell lines cultured in shaking flasks, insulin-like growth factor binding protein 2 (IGFBP2...
...Eto, Kyoto University, Kyoto, Japan email: kojieto@cira.kyoto-u.ac.jp Sandi Wong Kyoto University Chemokine CC motif ligand 5 (RANTES) (CCL5) Insulin-like growth factor (IGF) binding protein 2 (IGFBP2) Macrophage...
BioCentury | Jul 10, 2018
Distillery Therapeutics

Cancer

INDICATION: Small cell lung cancer Patient sample and cell culture studies suggest promoting IGFBP5 expression or inhibiting POU2F3 or IGF1R could help treat POU2F3-expressing small cell lung cancer (SCLC). In tumor samples from SCLC patients,...
BioCentury | Jun 27, 2018
Preclinical News

New small cell lung cancer subtype identified

In a Genes & Development paper , scientists at Cold Spring Harbor Laboratory identified a new subtype of small cell lung cancer defined by high levels of POU class 2 homeobox 3 (POU2F3; OCT11) and suggest...
BioCentury | May 11, 2018
Strategy

Takeda hits the gas

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management. On May...
BioCentury | Feb 6, 2018
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample and mouse studies suggest promoting IGFBP3 expression could help treat MYCN-driven neuroblastoma. In five MYCN-driven neuroblastoma cell lines, IGFBP3 encoded by a plasmid vector decreased viability compared with GFP. In...
BioCentury | Aug 18, 2017
Emerging Company Profile

Teasing out Th1

...researchers reported preclinical data from one of the programs, EP-201 , a vaccine against insulin-like growth factor binding protein 2 (IGFBP2...
...selectively activated Th1 cell responses and inhibited tumor growth to a greater extent than an IGFBP2-targeting...
...in an investigator-led Phase II study to treat ovarian cancer, an indication also associated with IGFBP2...
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

European science is showing early signs of translational growth, with VCs increasingly shifting their focus to preclinical assets. But investors are concerned the region still doesn’t have the supply of management talent or funding it...
Items per page:
1 - 10 of 165